|
Cannabis Campaigners' Guide News Database result:
|
|
UK: Terminal cancer patients in cannabis trials
Ananova
Wednesday 16 Jan 2002 Clinical trials of a new range of cannabis-based medicines are to be expanded to include patients with cancer pain. The treatments are already being given to patients with multiple sclerosis as part of a Phase Three trials programme. The British company developing the medicines, GW Pharmaceuticals, says more than 100 patients with terminal cancer will take part in the study at more than 20 UK centres. Dr Geoffrey Guy, executive chairman of the company, said: "This is a significant milestone for GW, and - we hope - for sufferers from cancer pain. "Cannabis-based medicine has the potential to provide considerable advantages over current medications to cancer patients. The potential market is very significant since approximately 40% of cancer sufferers at present have unmet needs in pain suppression." The company has also embarked on a new trial involving patients with brachial plexus injury, a severe form of nerve-damage pain which often results from motorcycle accidents. Phase Three trials are the final stage in preparing for a medicinal product to be approved by the Medicines Control Agency. Preliminary results from Phase Two MS and spinal cord injury trials have shown significant improvements in a range of symptoms.
After you have finished reading this article you can click here to go back.
|
This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!